vTv Therapeutics Receives Breakthrough Therapy Designation for TTP399
vTv Therapeutics (VTVT) - a clinical-stage biopharmaceutical company focused on the development of oral treatments for type 1 diabetes, psoriasis, and other diseases, announced that the U.S. FDA has granted Breakthrough Therapy designation for TTP399 as adjunctive therapy to insulin for the treatment of type 1 diabetes.
About vTv Therapeutics Product TTp399 . . .
This content is for paid subscribers.
Today’s Highlights April 13, 2021